Drug
Aflutinib clinical trials
Also written Furmonertinib and AST2818.
- studies test it
- 57
- open now
- 34
- in phase 3
- 8
- first study started
- 2016
Keep track of what changes. Save the aflutinib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Other names
Combined with it in one product
Studies by the year they started
57 studies that test it; most in 2022 (11)
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2017 | 2 |
| 2018 | 1 |
| 2019 | 4 |
| 2020 | 1 |
| 2021 | 9 |
| 2022 | 11 |
| 2023 | 3 |
| 2024 | 10 |
| 2025 | 6 |
| 2026 | 9 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 13
- Phase 2
- 37
- Phase 3
- 8
- Phase 4
- 1
- No phase
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 20 · Other 37
Allist Pharmaceuticals, Inc. (11) · Jiangsu Aosaikang Pharmaceutical Co., Ltd. (5) · ArriVent BioPharma, Inc. (3) · Sun Yat-sen University (3) · Hunan Province Tumor Hospital (3) · Peking University Cancer Hospital & Institute (2) · Fudan University (2) · Tianjin Medical University Cancer Institute and Hospital (2)
Often tested with
Tested in the same studies.
ASK-120067 (5) · Pemetrexed (4) · Carboplatin (3) · Bevacizumab (3) · Anlotinib (2) · Rifampin (1) · Itraconazole (1) · Sacituzumab tirumotecan (1)
Studies
Open first, then newest update. How each study uses aflutinib is read from its arms, and is right about nine times in ten.
Testing it · 57
- Firmonertinib Plus Chemotherapy for Unresectable EGFR PACC-Mutant Stage III Lung Cancer: A Phase II StudyNot yet recruitingPhase 2Hunan Province Tumor HospitalNCT07878871Written as Firmonertinib
- Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon MutationsRecruitingPhase 3ArriVent BioPharma, Inc.NCT07185997Written as Firmonertinib
- Study of Furmonertinib as Neoadjuvant Therapy for Resectable Stage Ⅱ-ⅢB EGFR Sensitive Mutant NSCLCRecruitingPhase 2Shanghai Zhongshan HospitalNCT05987826Written as Furmonertinib
- To Assess the Efficacy and Safety of Furmonertinib Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage II-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant ChemotherapyRecruitingPhase 3Allist Pharmaceuticals, Inc.NCT04853342Written as Drug: Furmonertinib 80 mg
- A Study to Assess the Efficacy and Safety of Firmonertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB - IIIB NSCLC With Uncommon Epidermal Growth Factor Receptor (EGFR) Mutations, Following Complete Surgical Resection With or Without Adjuvant Chemotherapy（FIRMOST）RecruitingPhase 3Allist Pharmaceuticals, Inc.NCT07010419Written as Firmonertinib
- A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain MetastasesRecruitingPhase 3Allist Pharmaceuticals, Inc.NCT06970639Written as Furmonertinib Mesilate Tablets
- Furmonertinib Plus Radiotherapy for EGFR+ NSCLC With Pleural EffusionNot yet recruitingPhase 2Jiangmen Central HospitalNCT07482605Written as Furmonertinib
- Firmonertinib Combined With Definitive Radiotherapy in Stage III Unresectable EGFR Uncommon Mutant Pulmonary AdenocarcinomaRecruitingPhase 2Hunan Cancer HospitalNCT07314216Written as Firmonertinib
- A Prospective Study of Firmonertinib as First-line Adaptive Therapy Guided by Dynamic ctDNA (MRD) Changes in Locally Advanced or Metastatic EGFR-mutated Non-small Cell Lung CancerNot yet recruitingPhase 2Anhui Provincial Cancer HospitalNCT07661173Written as Firmonertinib
- Vebreltinib Plus Furmonertinib in Patients With EGFR-mutated Advanced Non-small Cell Lung Cancer and High PD-L1 ExpressionRecruitingPhase 1/2Second Affiliated Hospital of Nanchang UniversityNCT07655622Written as Furmonertinib 80mg
- Firmonertinib in Perioperative Treatment of Resectable Stage II-IIIB EGFR-mutated Lung AdenocarcinomaNot yet recruitingPhase 2Peking University Cancer Hospital & InstituteNCT07622706Written as Firmonertinib 80mg qd oral for 8 weeks.
- Combining Furmonertinib With Local Therapy for Inoperable Early-stage Lung Cancer: A Phase II TrialNot yet recruitingPhase 2Shanghai Pulmonary Hospital, Shanghai, ChinaNCT07517640Written as furmonertinib
- Pulsatile High-dose Furmonertinib in EGFR-mutant NSCLC With Leptomeningeal MetastasisRecruitingNot applicableGuangzhou University of Traditional Chinese MedicineNCT07348965Written as Furmonertinib 320mg qod po
- Firmonertinib 160 mg in Patients With EGFR-Mutant Advanced NSCLC Demonstrating SD After 8 Week Induction With Firmonertinib 80 mgNot yet recruitingPhase 2Peking University Cancer Hospital & InstituteNCT07298148Written as Firmonertinib 160mg
- Furmonertinib Combined With Intrathecal Chemotherapy and Stereotactic Radiotherapy (SRT) for EGFR-Mutated NSCLC Patients With Brain Parenchymal and Leptomeningeal MetastasesRecruitingPhase 2Tianjin Medical University Cancer Institute and HospitalNCT07304739Written as Furmonertinib
- Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of ASKC202 With or Without ASK120067RecruitingPhase 1Jiangsu Aosaikang Pharmaceutical Co., Ltd.NCT05306132Written as ASK120067
- High-dose Furmonertinib or Combined With Chemotherapy in EGFR-mutant Advanced NSCLC After Disease Progression on Third-generation EGFR-TKIRecruitingPhase 2Jialei WangNCT06652048Written as Furmonertinib 160mg QD
- Sacituzumab Tirumotecan in Combination With Furmonertinib as Second-line Treatment for EGFR-mutant Advanced or Metastatic NSCLC After Failure of First-line Third-generation EGFR-TKI TherapyNot yet recruitingPhase 2Fudan UniversityNCT07193160Written as Furmonertinib
- A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid TumorsRecruitingPhase 1/2MediLink Therapeutics (Suzhou) Co., Ltd.NCT07169994Written as YL202 for injection; Furmonertinib Mesilate Tablets
- Firmonertinib Combined With Intrathecal Injection for the Treatment of EGFR Mutant NSCLC With Leptomeningeal MetastasesRecruitingPhase 4Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyNCT07092202Written as Firmonertinib
See all 57 studies that test aflutinib →
Given in every arm · 7 — aflutinib is usual care beside what is tested
- A Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC)RecruitingPhase 2Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.NCT07622186Written as Furmonertinib
- Evaluation of JSKN016 Combination Therapy in Subjects With NSCLCRecruitingPhase 1Jiangsu Alphamab Biopharmaceuticals Co., LtdNCT06868732Written as Furmonertinib Mesylate
- Furmonertinib 160mg vs 80mg + Chemotherapy in EGFR-Mutated NSCLC With Brain Metastases: Efficacy and Safety StudyNot yet recruitingPhase 2Tianjin Medical University Cancer Institute and HospitalNCT07365410Written as Furmonertinib
- A Study of MHB036C Combined With Anti-tumor Therapies in Patients With Advanced Lung CancerRecruitingPhase 1/2Minghui Pharmaceutical (Hangzhou) LtdNCT07229599Written as Furmonertinib
- A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or Recurrent Metastatic NSCLCRecruitingPhase 2RemeGen Co., Ltd.NCT06962865Written as Furmonertinib Mesilate Tablets Monotherapy
- IN10018 Combination Therapy in Advanced EGFR Mutation-positive NSCLCRecruitingPhase 1/2InxMed (Shanghai) Co., Ltd.NCT05994131Written as Furmonertinib
- Neoadjuvant Furmonertinib Plus Bevacizumab or Furmonertinib Monotherapy for Resectable and Potentially Resectable Stage III-IVA EGFR Mutation-Positive Lung AdenocarcinomaRecruitingPhase 2Shanghai Pulmonary Hospital, Shanghai, ChinaNCT05503667Written as Furmonertinib
Codes
What other systems call aflutinib · ClinicalTrials.gg INT001286
- MeSH (NLM) C000705711aflutinibConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) A49A7A5YN4FIRMONERTINIBConfirmed FDA, NLM
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000705711 | aflutinib | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | A49A7A5YN4 | FIRMONERTINIB | Confirmed FDA, NLM |
Also registered as firmonertinib mesylate (UNII Q09ZKD19V0).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.